Effect of commensals and probiotics on visceral sensitivity and pain in irritable bowel syndrome

Gut Microbes

Volumn 5, Issue 3, 2014, Pages

  Theodorou, Vassilia ^a,b   Belgnaoui, Afifa Ait ^a,b,c   Agostini, Simona ^a,b   Eutamene, Helene ^a,b  

^a CEMAGREF   (France)

^b TOXALIM RESEARCH CENTRE IN FOOD TOXICOLOGY   (France)

^c LALLEMAND SAS   (France)

Author keywords

Brain gut axis; Gut permeability; Intestinal barrier; Irritable bowel syndrome; Microbiota; Probiotics; Stress; Visceral pain

Indexed keywords

PROBIOTIC AGENT;

ANIMAL; DISEASE MODEL; HUMAN; IRRITABLE COLON; MICROBIOLOGY; MICROFLORA; PAIN; PATHOPHYSIOLOGY; SYMBIOSIS;

ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; IRRITABLE BOWEL SYNDROME; MICROBIOTA; PAIN; PROBIOTICS; SYMBIOSIS;

EID: 84905187670     PISSN: 19490976     EISSN: 19490984     Source Type: Journal    
DOI: 10.4161/gmic.29796     Document Type: Review

References (87)

1. Guarner F. The intestinal flora in inflammatory bowel disease: normal or abnormal? Curr Opin Gastroenterol 2005; 21:414-8;PMI D:15930980
2. Qin J, Li R, Raes J, Arumugam M, Burgdorf KS, Manichanh C, Nielsen T, Pons N, Levenez F, Yamada T, et al.; MetaHIT Consortium. A human gut microbial gene catalogue established by metagenomic sequencing. Nature 2010; 464:59-65;PMID:20203603; http://dx.doi.org/10.1038/ nature08821
3. Mondot S, de Wouters T, Doré J, Lepage P. The human gut microbiome and its dysfunctions. Dig Dis 2013; 31:278-85;PMID:24246975; http://dx.doi. org/10.1159/000354678
4. Manichanh C, Borruel N, Casellas F, Guarner F. The gut microbiota in IBD. Nat Rev Gastroenterol Hepatol 2012; 9:599-608;PMID:22907164; http:// dx.doi.org/10.1038/nrgastro.2012.152
5. Sokol H, Pigneur B, Watterlot L, Lakhdari O, Bermúdez-Humarán LG, Gratadoux JJ, Blugeon S, Bridonneau C, Furet JP, Corthier G, et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci U S A 2008; 105:16731-6;PMID:18936492; http:// dx.doi.org/10.1073/pnas.0804812105
6. Jeffery IB, O'Toole PW, Öhman L, Claesson MJ, Deane J, Quigley EM, Simrén M. An irritable bowel syndrome subtype defined by species-specific alterations in faecal microbiota. Gut 2012; 61:997-1006;PMID:22180058; http://dx.doi.org/10.1136/ gutjnl-2011-301501
7. Kassinen A, Krogius-Kurikka L, Mäkivuokko H, Rinttilä T, Paulin L, Corander J, Malinen E, Apajalahti J, Palva A. The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects. Gastroenterology 2007; 133:24-33;PMID:17631127; http://dx.doi. org/10.1053/j.gastro.2007.04.005
8. Kerckhoffs AP, Samsom M, van der Rest ME, de Vogel J, Knol J, Ben-Amor K, Akkermans LM. Lower Bifidobacteria counts in both duodenal mucosa-associated and fecal microbiota in irritable bowel syndrome patients. World J Gastroenterol 2009; 15:2887-92;PMID:19533811; http://dx.doi. org/10.3748/wjg.15.2887
9. Malinen E, Rinttilä T, Kajander K, Mättö J, Kassinen A, Krogius L, Saarela M, Korpela R, Palva A. Analysis of the fecal microbiota of irritable bowel syndrome patients and healthy controls with real-time PCR. Am J Gastroenterol 2005; 100:373-82;PMI D:15667495; ht t p://dx. doi.org/10.1111/j.1572-0241.2005.40312.x
10. Mättö J, Maunuksela L, Kajander K, Palva A, Korpela R, Kassinen A, Saarela M. Composition and temporal stability of gastrointestinal microbiota in irritable bowel syndrome--a longitudinal study in IBS and control subjects. FEMS Immunol Med Microbiol 2005; 43:213-22;PMID:15747442; http://dx.doi. org/10.1016/j.femsim.2004.08.009
11. Rajilic-Stojanovic M, Biagi E, Heilig HG, Kajander K, Kekkonen RA, Tims S, de Vos WM. Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome. Gastroenterology 2011; 141:1792-801; PMID:21820992; http://dx.doi.org/10.1053/j. gastro.2011.07.043
12. Chassard C, Dapoigny M, Scott KP, Crouzet L, Del'homme C, Marquet P, Martin JC, Pickering G, Ardid D, Eschalier A, et al. Functional dysbiosis within the gut microbiota of patients with constipated-irritable bowel syndrome. Aliment Pharmacol Ther 2012; 35:828-38;PMI D:22315951; http:// dx.doi.org/10.1111/j.1365-2036.2012.05007.x
13. Meyrat P, Safroneeva E, Schoepfer AM. Rifaximin treatment for the irritable bowel syndrome with a positive lactulose hydrogen breath test improves symptoms for at least 3 months. Aliment Pharmacol Ther 2012; 36:1084-93;PMID:23066911; http:// dx.doi.org/10.1111/apt.12087
14. O'Mahony L, McCarthy J, Kelly P, Hurley G, Luo F, Chen K, O'Sullivan GC, Kiely B, Collins JK, Shanahan F, et al. Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology 2005; 128:541-51;PMI D:15765388; http://dx.doi. org/10.1053/j.gastro.2004.11.050
15. Saulnier DM, Ringel Y, Heyman MB, Foster JA, Bercik P, Shulman RJ, Versalovic J, Verdu EF, Dinan TG, Hecht G, et al. The intestinal microbiome, probiotics and prebiotics in neurogastroenterology. Gut Microbes 2013; 4:17-27;PMID:23202796; http:// dx.doi.org/10.4161/gmic.22973
16. Mayer EA. Gut feelings: the emerging biology of gut-brain communication. Nat Rev Neurosci 2011; 12:453-66;PMID:21750565; http://dx.doi. org/10.1038/nrn3071
17. Saito YA, Schoenfeld P, Locke GR 3 rd. The epidemiology of irritable bowel syndrome in North America: a systematic review. Am J Gastroenterol 2002; 97:1910-5;PMI D:12190153
18. Hungin AP, Chang L, Locke GR, Dennis EH, Barghout V. Irritable bowel syndrome in the United States: prevalence, symptom patterns and impact. Aliment Pharmacol Ther 2005; 21:1365-75;PMI D:15932367; http://dx.doi. org/10.1111/j.1365-2036.2005.02463.x
19. Robinson DR, Gebhart GF. Inside information: the unique features of visceral sensation. Mol Interv 2008; 8:242-53;PMI D:19015388; http://dx.doi. org/10.1124/mi.8.5.9
20. Ritchie JA, Ardran GM, Truelove SC. Observations on experimentally induced colonic pain. Gut 1972; 13:841-7;PMID:5087084
21. van Wanrooij SJ, Wouters MM, Van Oudenhove L, Vanbrabant W, Mondelaers S, Kollmann P, Kreutz F, Schemann M, Boeckxstaens GE. Sensitivity testing in irritable bowel syndrome with rectal capsaicin stimulations: role of TRPV1 upregulation and sensitization in visceral hypersensitivity? Am J Gastroenterol 2014; 109:99-109;PMID:24189713; http://dx.doi. org/10.1038/ajg.2013.371
22. Palsson OS, Baggish JS, Turner MJ, Whitehead WE. IBS patients show frequent fluctuations between loose/watery and hard/lumpy stools: implications for treatment. Am J Gastroenterol 2012; 107:286-95;PMID:22068664; http://dx.doi.org/10.1038/ ajg.2011.358
23. Gasbarrini A, Lauritano EC, Garcovich M, Sparano L, Gasbarrini G. New insights into the pathophysiology of IBS: intestinal microflora, gas production and gut motility. Eur Rev Med Pharmacol Sci 2008; 12 (Suppl 1):111-7;PMID:18924450
24. Mayer EA. Gut feelings: the emerging biology of gut-brain communication. Nat Rev Neurosci 2011; 12:453-66;PMID:21750565; http://dx.doi. org/10.1038/nrn3071
25. Barbara G, Cremon C, De Giorgio R, Dothel G, Zecchi L, Bellacosa L, Carini G, Stanghellini V, Corinaldesi R. Mechanisms underlying visceral hypersensitivity in irritable bowel syndrome. Curr Gastroenterol Rep 2011; 13:308-15;PMID:21537962; http://dx.doi. org/10.1007/s11894-011-0195-7
26. Mayer EA. Emerging disease model for functional gastrointestinal disorders. Am J Med 1999; 107(5A):12S-9S;PMID:10588168; http://dx.doi. org/10.1016/S0002-9343(99)00277-6
27. Kellow JE, Azpiroz F, Delvaux M, Gebhart GF, Mertz HR, Quigley EM, Smout AJ. Applied principles of neurogastroenterology: physiology/motility sensation. Gastroenterology 2006; 130:1412-20; PMID:16678555; http://dx.doi.org/10.1053/j. gastro.2005.08.061
28. Grundy D, Al-Chaer ED, Aziz Q, Collins SM, Ke M, Taché Y, Wood JD. Fundamentals of neurogastroenterology: basic science. Gastroenterology 2006; 130:1391-411;PMID:16678554; http://dx.doi. org/10.1053/j.gastro.2005.11.060
29. Feng B, La JH, Schwartz ES, Gebhart GF. Irritable bowel syndrome: methods, mechanisms, and pathophysiology. Neural and neuro-immune mechanisms of visceral hypersensitivity in irritable bowel syndrome. Am J Physiol Gastrointest Liver Physiol 2012; 302:G1085-98;PMID:22403791; http://dx.doi. org/10.1152 /ajpgi.00542.2011
30. Hertig VL, Cain KC, Jarrett ME, Burr RL, Heitkemper MM. Daily stress and gastrointestinal symptoms in women with irritable bowel syndrome. Nurs Res 2007; 56:399-406;PMID:18004186; http://dx.doi. org/10.1097/01.NNR.0000299855.60053.88
31. Chaudhary NA, Truelove SC. Human colonic motility. A comparative study of normal subjects, patients with ulcerative colitis, and patients with the irritable colon syndrome. Gastroenterology 1968; 54:777-8; PMID:5659823
32. Spiller RC, Jenkins D, Thornley JP, Hebden JM, Wright T, Skinner M, Neal KR. Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome. Gut 2000; 47:804-11; PMID:11076879; http://dx.doi.org/10.1136/ gut.47.6.804
33. Marshall JK, Thabane M, Garg AX, Clark W, Meddings J, Collins SM; WEL Investigators. Intestinal permeability in patients with irritable bowel syndrome after a waterborne outbreak of acute gastroenteritis in Walkerton, Ontario. Aliment Pharmacol Ther 2004; 20:1317-22;PMI D:15606393; http:// dx.doi.org/10.1111/j.1365-2036.2004.02284.x
34. Villani AC, Lemire M, Thabane M, Belisle A, Geneau G, Garg AX, Clark WF, Moayyedi P, Collins SM, Franchimont D, et al. Genetic risk factors for postinfectious irritable bowel syndrome following a waterborne outbreak of gastroenteritis. Gastroenterology 2010; 138:1502-13;PMID:20044998; http://dx.doi. org/10.1053/j.gastro.2009.12.049
35. Spiller R, Garsed K. Postinfectious irritable bowel syndrome. Gastroenterology 2009; 136:1979-88; http://dx.doi.org/10.1053/j.gastro.2009.02.074; PMID:19457422
36. Jalanka-Tuovinen J, Salojärvi J, Salonen A, Immonen O, Garsed K, Kelly FM, Zaitoun A, Palva A, Spiller RC, de Vos WM. Faecal microbiota composition and host-microbe cross-talk following gastroenteritis and in postinfectious irritable bowel syndrome. Gut 2013; In press: http://dx.doi.org/10.1136/ gutjnl-2013-305994;PMID:24310267
37. Schoepfer AM, Schaffer T, Seibold-Schmid B, Müller S, Seibold F. Antibodies to flagellin indicate reactivity to bacterial antigens in IBS patients. Neurogastroenterol Motil 2008; 20:1110-8;PMID:18694443; http://dx.doi. org/10.1111/j.1365-2982.2008.01166.x
38. Matsunami M, Tarui T, Mitani K, Nagasawa K, Fukushima O, Okubo K, Yoshida S, Takemura M, Kawabata A. Luminal hydrogen sulfide plays a pronociceptive role in mouse colon. Gut 2009; 58:751-61;PMID:18852258; http://dx.doi.org/10.1136/ gut.2007.144543
39. King TS, Elia M, Hunter JO. Abnormal colonic fermentation in irritable bowel syndrome. Lancet 1998; 352:1187-9;PMID:9777836; http://dx.doi. org/10.1016/S0140-6736(98) 02146-1
40. Lin HC. Small intestinal bacterial overgrowth: a framework for understanding irritable bowel syndrome. JAMA 2004; 292:852-8;PMID:15316000; http://dx.doi.org/10.1001/jama.292.7.852
41. Pimentel M, Chow EJ, Lin HC. Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome. Am J Gastroenterol 2000; 95:3503-6;PMID:11151884; http://dx.doi. org/10.1111/j.1572-0241.2000.03368.x
42. Pimentel M, Chatterjee S, Chow EJ, Park S, Kong Y. Neomycin improves constipation-predominant irritable bowel syndrome in a fashion that is dependent on the presence of methane gas: subanalysis of a double-blind randomized controlled study. Dig Dis Sci 2006; 51:1297-301;PMID:16832617; http://dx.doi. org/10.1007/s10620-006-9104-6
43. Pimentel M, Chow EJ, Lin HC. Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome. a doubleblind, randomized, placebo-controlled study. Am J Gastroenterol 2003; 98:412-9;PMID:12591062
44. Ward KM, Rounthwaite FJ. Neomycin ototoxicity. Ann Otol Rhinol Laryngol 1978; 87:211-5; PMID:646289
45. Yang J, Lee HR, Low K, Chatterjee S, Pimentel M. Rifaximin versus other antibiotics in the primary treatment and retreatment of bacterial overgrowth in IBS. Dig Dis Sci 2008; 53:169-74;PMID:17520365; http://dx.doi.org/10.1007/s10620-007-9839-8
46. Pimentel M, Lembo A, Chey WD, Zakko S, Ringel Y, Yu J, Mareya SM, Shaw AL, Bortey E, Forbes WP; TARGET Study Group. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med 2011; 364:22-32;PMID:21208106; http://dx.doi.org/10.1056/ NEJMoa1004409
47. Meyrat P, Safroneeva E, Schoepfer AM. Rifaximin treatment for the irritable bowel syndrome with a positive lactulose hydrogen breath test improves symptoms for at least 3 months. Aliment Pharmacol Ther 2012; 36:1084-93;PMID:23066911; http:// dx.doi.org/10.1111/apt.12087
48. Tana C, Umesaki Y, Imaoka A, Handa T, Kanazawa M, Fukudo S. Altered profiles of intestinal microbiota and organic acids may be the origin of symptoms in irritable bowel syndrome. Neurogastroenterol Motil 2010; 22:512-9, e114-5;PMID:19903265
49. Treem WR, Ahsan N, Kastoff G, Hyams JS. Fecal short-chain fatty acids in patients with diarrhea-predominant irritable bowel syndrome: in vitro studies of carbohydrate fermentation. J Pediatr Gastroenterol Nutr 1996; 23:280-6;PMID:8890079; http:// dx.doi.org/10.1097/00005176-199610000-00013
50. Vanhoutvin SA, Troost FJ, Kilkens TO, Lindsey PJ, Hamer HM, Jonkers DM, Venema K, Brummer RJ. The effects of butyrate enemas on visceral perception in healthy volunteers. Neurogastroenterol Motil 2009; 21:952-e76;PMID:19460106; http://dx.doi. org/10.1111/j.1365-2982.2009.01324.x
51. Koide A, Yamaguchi T, Odaka T, Koyama H, Tsuyuguchi T, Kitahara H, Ohto M, Saisho H. Quantitative analysis of bowel gas using plain abdominal radiograph in patients with irritable bowel syndrome. Am J Gastroenterol 2000; 95:1735-41;PMID:10925977; http://dx.doi. org/10.1111/j.1572-0241.2000.02189.x
52. Crouzet L, Gaultier E, Del'Homme C, Cartier C, Delmas E, Dapoigny M, Fioramonti J, BernalierDonadille A. The hypersensitivity to colonic distension of IBS patients can be transferred to rats through their fecal microbiota. Neurogastroenterol Motil 2013; 25:e272-82;PMID:23433203; http://dx.doi. org/10.1111/nmo.12103
53. Ford AC, Talley NJ. Mucosal inflammation as a potential etiological factor in irritable bowel syndrome: a systematic review. J Gastroenterol 2011; 46:421-31;PMID:21331765; http://dx.doi. org/10.1007/s00535-011-0379-9
54. Cervero F, Jänig W. Visceral nociceptors: a new world order? Trends Neurosci 1992; 15:374-8;PMID:1279857; http://dx.doi. org/10.1016/0166-2236(92)90182-8
55. Verdú EF, Bercik P, Verma-Gandhu M, Huang XX, Blennerhassett P, Jackson W, Mao Y, Wang L, Rochat F, Collins SM. Specific probiotic therapy attenuates antibiotic induced visceral hypersensitivity in mice. Gut 2006; 55:182-90;PMID:16105890; http:// dx.doi.org/10.1136/gut.2005.066100
56. O'Sullivan M, Clayton N, Breslin NP, Harman I, Bountra C, McLaren A, O'Morain CA. Increased mast cells in the irritable bowel syndrome. Neurogastroenterol Motil 2000; 12:449-57;PMID:11012945; http://dx.doi. org/10.1046/j.1365-2982.2000.00221.x
57. Weston AP, Biddle WL, Bhatia PS, Miner PB Jr. Terminal ileal mucosal mast cells in irritable bowel syndrome. Dig Dis Sci 1993; 38:1590-5;PMID:8359068; http://dx.doi.org/10.1007/ BF01303164
58. Langhorst J, Junge A, Rueffer A, Wehkamp J, Foell D, Michalsen A, Musial F, Dobos GJ. Elevated human beta-defensin-2 levels indicate an activation of the innate immune system in patients with irritable bowel syndrome. Am J Gastroenterol 2009; 104:404-10;PMID:19174795; http://dx.doi.org/10.1038/ ajg.2008.86
59. Collins SM. The immunomodulation of enteric neuromuscular function: implications for motility and inflammatory disorders. Gastroenterology 1996; 111:1683-99;PMID:8942751; http://dx.doi. org/10.1016/S0016-5085(96)70034-3
60. Barbara G, Stanghellini V, De Giorgio R, Cremon C, Cottrell GS, Santini D, Pasquinelli G, MorselliLabate AM, Grady EF, Bunnett NW, et al. Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology 2004; 126:693-702; PMID:14988823; http://dx.doi.org/10.1053/j. gastro.2003.11.055
61. Buhner S, Li Q, Vignali S, Barbara G, De Giorgio R, Stanghellini V, Cremon C, Zeller F, Langer R, Daniel H, et al. Activation of human enteric neurons by supernatants of colonic biopsy specimens from patients with irritable bowel syndrome. Gastroenterology 2009; 137:1425-34;PMID:19596012; http://dx.doi. org/10.1053/j.gastro.2009.07.005
62. Macfarlane GT, Allison C, Gibson SA, Cummings JH. Contribution of the microflora to proteolysis in the human large intestine. J Appl Bacteriol 1988; 64:37-46;PMID:3127369; http://dx.doi. org/10.1111/j.1365-2672.1988.tb02427.x
63. Róka R, Rosztóczy A, Leveque M, Izbéki F, Nagy F, Molnár T, Lonovics J, Garcia-Villar R, Fioramonti J, Wittmann T, et al. A pilot study of fecal serine-protease activity: a pathophysiologic factor in diarrhea-predominant irritable bowel syndrome. Clin Gastroenterol Hepatol 2007; 5:550-5;PMID:17336590; http://dx.doi.org/10.1016/j. cgh.2006.12.004
64. Gecse K, Róka R, Ferrier L, Leveque M, Eutamene H, Cartier C, Ait-Belgnaoui A, Rosztóczy A, Izbéki F, Fioramonti J, et al. Increased faecal serine protease activity in diarrhoeic IBS patients: a colonic lumenal factor impairing colonic permeability and sensitivity. Gut 2008; 57:591-9;PMID:18194983; http://dx.doi. org/10.1136/gut.2007.140210
65. Annaházi A, Ferrier L, Bézirard V, Lévêque M, Eutamène H, Ait-Belgnaoui A, Coëffier M, Ducrotté P, Róka R, Inczefi O, et al. Luminal cysteine-proteases degrade colonic tight junction structure and are responsible for abdominal pain in constipation-predominant IBS. Am J Gastroenterol 2013; 108:1322-31;PMID:23711626; http://dx.doi.org/10.1038/ ajg.2013.152
66. Piche T, Barbara G, Aubert P, Bruley des Varannes S, Dainese R, Nano JL, Cremon C, Stanghellini V, De Giorgio R, Galmiche JP, et al. Impaired intestinal barrier integrity in the colon of patients with irritable bowel syndrome: involvement of soluble mediators. Gut 2009; 58:196-201;PMID:18824556; http:// dx.doi.org/10.1136/gut.2007.140806
67. Zhou Q, Zhang B, Verne GN. Intestinal membrane permeability and hypersensitivity in the irritable bowel syndrome. Pain 2009; 146:41-6; PMID:19595511; http://dx.doi.org/10.1016/j. pain.2009.06.017
68. Martínez C, Lobo B, Pigrau M, Ramos L, GonzálezCastro AM, Alonso C, Guilarte M, Guilá M, de Torres I, Azpiroz F, et al. Diarrhoea-predominant irritable bowel syndrome: an organic disorder with structural abnormalities in the jejunal epithelial barrier. Gut 2013; 62:1160-8;PMID:22637702; http:// dx.doi.org/10.1136/gutjnl-2012-302093
69. Martínez C, Vicario M, Ramos L, Lobo B, Mosquera JL, Alonso C, Sánchez A, Guilarte M, Antolín M, de Torres I, et al. The jejunum of diarrhea-predominant irritable bowel syndrome shows molecular alterations in the tight junction signaling pathway that are associated with mucosal pathobiology and clinical manifestations. Am J Gastroenterol 2012; 107:736-46;PMI D:22415197; http://dx.doi.org/10.1038/ ajg.2011.472
70. Ait-Belgnaoui A, Bradesi S, Fioramonti J, Theodorou V, Bueno L. Acute stress-induced hypersensitivity to colonic distension depends upon increase in paracellular permeability: role of myosin light chain kinase. Pain 2005; 113:141-7;PMID:15621374; http:// dx.doi.org/10.1016/j.pain.2004.10.002
71. FAO/WHO Working Group Guidelines for the evaluation of probiotics in food. London, Ontario, Canada Abvailable at ftp://ftp.fao.org/es/esn/food/ wgreport2.pdf.
72. Hungin AP, Mulligan C, Pot B, Whorwell P, Agréus L, Fracasso P, Lionis C, Mendive J, Philippart de Foy JM, Rubin G, et al. European Society for Primary Care Gastroenterology. Systematic review: probiotics in the management of lower gastrointestinal symptoms in clinical practice-an evidencebased international guide. Aliment Pharmacol Ther 2013; 38:864-86;PMID:23981066; http://dx.doi. org/10.1111/apt.12460
73. Vahabnezhad E, Mochon AB, Wozniak LJ, Ziring DA. Lactobacillus bacteremia associated with probiotic use in a pediatric patient with ulcerative colitis. J Clin Gastroenterol 2013; 47:437-9;PMID:23426446; http://dx.doi.org/10.1097/MCG.0b013e318279abf0
74. Theodorakopoulou M, Perros E, GiamarellosBourboulis EJ, Dimopoulos G. Controversies in the management of the critically ill: the role of probiotics. Int J Antimicrob Agents 2013; 42(Suppl):S41-4; PMID:23664676; http://dx.doi.org/10.1016/j. ijantimicag.2013.04.010
75. Morrow LE, Gogineni V, Malesker MA. Probiotic, prebiotic, and synbiotic use in critically ill patients. Curr Opin Crit Care 2012; 18:186-91; PMID:22343306; http://dx.doi.org/10.1097/ MCC.0b013e3283514b17
76. Kamiya T, Wang L, Forsythe P, Goettsche G, Mao Y, Wang Y, Tougas G, Bienenstock J. Inhibitory effects of Lactobacillus reuteri on visceral pain induced by colorectal distension in Sprague-Dawley rats. Gut 2006; 55:191-6;PMID:16361309; http://dx.doi. org/10.1136/gut.2005.070987
77. Rousseaux C, Thuru X, Gelot A, Barnich N, Neut C, Dubuquoy L, Dubuquoy C, Merour E, Geboes K, Chamaillard M, et al. Lactobacillus acidophilus modulates intestinal pain and induces opioid and cannabinoid receptors. Nat Med 2007; 13:35-7; PMID:17159985; http://dx.doi.org/10.1038/nm1521
78. Larauche M, Mulak A, Taché Y. Stress-related alterations of visceral sensation: animal models for irritable bowel syndrome study. J Neurogastroenterol Motil 2011; 17:213-34;PMID:21860814; http://dx.doi. org/10.5056/jnm.2011.17.3.213
79. Gareau MG, Silva MA, Perdue MH. Pathophysiological mechanisms of stressinduced intestinal damage. Curr Mol Med 2008; 8:274-81;PMID:18537635; http://dx.doi. org/10.2174/156652408784533760
80. Zareie M, Johnson-Henry K, Jury J, Yang PC, Ngan BY, McKay DM, Soderholm JD, Perdue MH, Sherman PM. Probiotics prevent bacterial translocation and improve intestinal barrier function in rats following chronic psychological stress. Gut 2006; 55:1553-60;PMID:16638791; http://dx.doi. org/10.1136/gut.2005.080739
81. Gareau MG, Jury J, MacQueen G, Sherman PM, Perdue MH. Probiotic treatment of rat pups normalises corticosterone release and ameliorates colonic dysfunction induced by maternal separation. Gut 2007; 56:1522-8;PMID:17339238; http://dx.doi. org/10.1136/gut.2006.117176
82. Ait-Belgnaoui A, Han W, Lamine F, Eutamene H, Fioramonti J, Bueno L, Theodorou V. Lactobacillus farciminis treatment suppresses stress induced visceral hypersensitivity: a possible action through interaction with epithelial cell cytoskeleton contraction. Gut 2006; 55:1090-4;PMID:16507583; http:// dx.doi.org/10.1136/gut.2005.084194
83. Ait-Belgnaoui A, Eutamene H, Houdeau E, Bueno L, Fioramonti J, Theodorou V. Lactobacillus farciminis treatment attenuates stress-induced overexpression of Fos protein in spinal and supraspinal sites after colorectal distension in rats. Neurogastroenterol Motil 2009; 21:567-73, e18-9;PMID:19309441; ht t p://dx. doi.org/10.1111/j.1365-2982.2009.01280.x
84. Eutamene H, Lamine F, Chabo C, Theodorou V, Rochat F, Bergonzelli GE, Corthésy-Theulaz I, Fioramonti J, Bueno L. Synergy between Lactobacillus paracasei and its bacterial products to counteract stress-induced gut permeability and sensitivity increase in rats. J Nutr 2007; 137:1901-7; PMID:17634262
85. McKernan DP, Fitzgerald P, Dinan TG, Cryan JF. The probiotic Bifidobacterium infantis 35624 displays visceral antinociceptive effects in the rat. Neurogastroenterol Motil 2010; 22:1029-35, e268;PMID:20518856; http://dx.doi. org/10.1111/j.1365-2982.2010.01520.x
86. O'Mahony L, McCarthy J, Kelly P, Hurley G, Luo F, Chen K, O'Sullivan GC, Kiely B, Collins JK, Shanahan F, et al. Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology 2005; 128:541-51;PMI D:15765388; http://dx.doi. org/10.1053/j.gastro.2004.11.050
87. Agostini S, Goubern M, Tondereau V, SalvadorCartier C, Bezirard V, Lévèque M, Keränen H, Theodorou V, Bourdu-Naturel S, Goupil-Feuillerat N, et al. A marketed fermented dairy product containing Bifidobacterium lactis CNCM I-2494 suppresses gut hypersensitivity and colonic barrier disruption induced by acute stress in rats. Neurogastroenterol Motil 2012; 24:376-e172;PMID:22272920; http:// dx.doi.org/10.1111/j.1365-2982.2011.01865.x